Mizuho Securities Starts Terns Pharmaceuticals (TERN) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
Tweet
Share
E-mailGet Alerts TERN Hot Sheet
Price: $52.95 --0%
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
Mizuho Securities analyst Graig Suvannavejh initiates coverage on Terns Pharmaceuticals (NASDAQ: TERN) with a Buy rating and a price target of $16.00.
For an analyst ratings summary and ratings history on Terns Pharmaceuticals click here. For more ratings news on Terns Pharmaceuticals click here.
Shares of Terns Pharmaceuticals closed at $11.86 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Citi Starts TCL Electronics Holdings (1070:HK) at Buy
- Bernstein SocGen Group Starts Pfizer Ltd (PFIZ:IN) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
